Remove Diagnostic Remove Diagnostic Imaging Remove Pharmaceutical
article thumbnail

123 organizations come out in support of FIND Act aimed at strengthening diagnostic imaging pay

Radiology Business

Backers include societies representing radiologists and nuclear medicine professionals, device manufacturers, patient advocacy groups, and pharmaceutical companies.

article thumbnail

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

Imaging Technology

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GE HealthCare Announces Agreement to Acquire MIM Software

Imaging Technology

GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.

article thumbnail

Diagnostic radiology physicians net $54M in industry payments

AuntMinnie

Pharmaceutical industry companies were involved in payments to diagnostic radiolog.

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.

article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

produced, non-uranium based Mo-99 for use in diagnostic imaging. RadioGenix Systems have generated almost two million doses of Tc-99m for patients’ diagnostic imaging studies to date, with utilization continuing to steadily increase. Our track record of success includes our program to supply U.S.-produced,

Medical 98
article thumbnail

Clarity Pharmaceuticals to Begin Phase 3 Trial for New PSMA PET Agent for Prostate Cancer

Diagnostic Imaging

The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.